All In Biotech

Free tool

FAERS Monitor: Atropine (Autoinjector)

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 212319 or its brand name (Atropine (Autoinjector), Atropine). Reports on generic versions are filed under their own applications.

Reports

1,487

Serious

1,393

94% of reports

Hospitalization

805

Death reported

391

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death346
  • therapy interrupted158
  • therapy cessation113
  • hospitalisation95
  • surgery72
  • condition aggravated53
  • pneumonia44
  • fall36
  • cerebrovascular accident31
  • covid-1931
  • infection25
  • pain25
  • fatigue21
  • intentional dose omission18
  • dyspnoea17

Reports by year received

View as table
YearReports
200422
20051
20061
20092
20103
20122
20134
20146
20153
20164
201841
2019400
2020562
2021420
20226
20233
20244
20263

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,672 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
therapy interruptedSignal15831.327.04,616
therapy cessationSignal11331.226.13,274
surgerySignal7217.413.91,098
intentional dose omissionSignal188.95.6119
hospitalisationSignal958.87.2649
deathSignal3465.75.21,387
cerebrovascular accidentSignal312.61.829
covid-19Signal312.51.827
condition aggravatedSignal532.51.945
infectionSignal252.41.720
pneumonia441.91.419
fall361.51.16
pain250.60.48
dyspnoea170.40.313
fatigue210.40.221

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.